www.MigraineTreatmentReport.com
https://clinicaltrials.gov/ct2/show/NCT04464707
https://clinicaltrials.gov/ct2/show/NCT04464707?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Interventions : Drug: Fremanezumab; Drug: Placebo
Sponsor : Teva Branded Pharmaceutical Products R&D, Inc.
Not yet recruiting
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
NCT04464707
Thu, 09 Jul 2020 12:00:00 EDT
Last Update Posted: 07/09/20 08:37AM
https://clinicaltrials.gov/ct2/show/NCT04384367?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Interventions : Drug: Rizatriptan 10 mg + Naproxen 550mg; Drug: Maxalt 10Mg Tablet; Drug: Flanax 550mg; Drug: Placebo oral tablet
Sponsor : Eurofarma Laboratorios S.A.
Not yet recruiting
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
NCT04384367
Tue, 12 May 2020 12:00:00 EDT
Last Update Posted: 05/12/20 06:48AM
https://clinicaltrials.gov/ct2/show/NCT04360044?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Conditions : Migraine; Cannabis; THC; CBD
Interventions : Drug: THC ~4%; Drug: CBD ~6%; Drug: THC ~4% and CBD ~6%; Drug: Sham Cannabis
Sponsors : University of California, San Diego; Migraine Research Foundation
Not yet recruiting
Cannabis for Acute Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial
NCT04360044
Fri, 24 Apr 2020 12:00:00 EDT
Last Update Posted: 04/24/20 07:26AM
https://clinicaltrials.gov/ct2/show/NCT04355117?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Intervention : Drug: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
Sponsor : Otsuka Pharmaceutical Co., Ltd.
Recruiting
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
NCT04355117
Tue, 21 Apr 2020 12:00:00 EDT
Last Update Posted: 04/21/20 06:59AM
https://clinicaltrials.gov/ct2/show/NCT04161807?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Chronic Migraine
Intervention : Device: Nerivio
Sponsor : Theranica
Recruiting
Efficacy and Safety of Nerivio™, a Remote Electrical Neuromodulation Device, for Acute Treatment of Migraine in People With Chronic Migraine: an Open Label, Single Arm, Multicenter Study
NCT04161807
Wed, 13 Nov 2019 12:00:00 EST
Last Update Posted: 11/13/19 12:03PM
https://clinicaltrials.gov/ct2/show/NCT04153409?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Acute Migraine
Interventions : Drug: LAT8881; Drug: Placebo
Sponsor : Lateral Pharma Pty Ltd
Recruiting
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
NCT04153409
Wed, 06 Nov 2019 12:00:00 EST
Last Update Posted: 11/06/19 08:27AM
https://clinicaltrials.gov/ct2/show/NCT04089761?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Acute Migraine
Intervention : Device: Nerivio
Sponsor : Theranica
Not yet recruiting
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
NCT04089761
Fri, 13 Sep 2019 12:00:00 EDT
Last Update Posted: 09/13/19 06:52AM
https://clinicaltrials.gov/ct2/show/NCT04068051?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Intervention : Drug: AXS-07
Sponsor : Axsome Therapeutics, Inc.
Recruiting
Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine
NCT04068051
Mon, 26 Aug 2019 12:00:00 EDT
Last Update Posted: 08/28/19 11:26AM
https://clinicaltrials.gov/ct2/show/NCT03874351?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine Disorders
Intervention : Device: non-invasive transcranial direct current stimulation (tDCS)
Sponsors : MJHS Institute for Innovation in Palliative Care; New York Headache Center
Not yet recruiting
A Study of Home-Delivered Neurostimulation for Migraine
NCT03874351
Thu, 14 Mar 2019 12:00:00 EDT
Last Update Posted: 11/18/19 11:23AM
https://clinicaltrials.gov/ct2/show/NCT03972124?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Chronic Migraine
Interventions : Drug: CBD 50 mg BID; Drug: CBD 100 mg BID; Drug: Placebo
Sponsor : University of Calgary
Not yet recruiting
Cannabis for the Prophylactic Treatment of Migraine
NCT03972124
Mon, 03 Jun 2019 12:00:00 EDT
Last Update Posted: 06/03/19 07:42AM
https://clinicaltrials.gov/ct2/show/NCT03927144?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Episodic Migraine
Interventions : Drug: Erenumab; Drug: Oral Prophylactic
Sponsors : Amgen; Novartis
Not yet recruiting
Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients
NCT03927144
Thu, 25 Apr 2019 12:00:00 EDT
Last Update Posted: 04/25/19 07:33AM
https://clinicaltrials.gov/ct2/show/NCT03919045?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Chronic Migraine
Interventions : Drug: Saline injection; Procedure: Placebo
Sponsor : Göteborg University
Not yet recruiting
Saline Injections for Prophylactic Treatment of Chronic Migraine
NCT03919045
Thu, 18 Apr 2019 12:00:00 EDT
Last Update Posted: 04/18/19 08:20AM
https://clinicaltrials.gov/ct2/show/NCT03902496?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Interventions : Other: HIT-6 Questionnaire; Device: Avulux Spectacles; Device: Sham Spectacles
Sponsor : Avulux, Inc.
Recruiting
Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.
NCT03902496
Thu, 04 Apr 2019 12:00:00 EDT
Last Update Posted: 04/04/19 07:50AM
https://clinicaltrials.gov/ct2/show/NCT03900611?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Intervention : Device: peripheral electrical stimulation
Sponsor : Taipei Veterans General Hospital, Taiwan
Not yet recruiting
Peripheral Electrical Stimulation for Migraine Prevention
NCT03900611
Wed, 03 Apr 2019 12:00:00 EDT
Last Update Posted: 04/03/19 07:39AM
https://clinicaltrials.gov/ct2/show/NCT03901482?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Conditions : Migraine; Migraine With Aura; Migraine Without Aura
Interventions : Drug: Dihydroergotamine; Drug: Placebos
Sponsor : Satsuma Pharmaceuticals, Inc.
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
NCT03901482
Wed, 03 Apr 2019 12:00:00 EDT
Last Update Posted: 04/03/19 07:39AM
https://clinicaltrials.gov/ct2/show/NCT03896256?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine Headache With Intractable Migraine
Intervention : Drug: ketamine infusion
Sponsor : Thomas Jefferson University
Enrolling by invitation
Ketamine for Refractory Chronic Migraine: a Pilot Study
NCT03896256
Fri, 29 Mar 2019 12:00:00 EDT
Last Update Posted: 03/29/19 09:48AM
https://clinicaltrials.gov/ct2/show/NCT03896009?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine
Interventions : Drug: AXS-07 (MoSEIC meloxicam and rizatriptan); Drug: Meloxicam; Drug: Rizatriptan; Drug: Placebo
Sponsor : Axsome Therapeutics, Inc.
Recruiting
Maximizing Outcomes in Treating Acute Migraine
NCT03896009
Fri, 29 Mar 2019 12:00:00 EDT
Last Update Posted: 03/29/19 09:48AM
https://clinicaltrials.gov/ct2/show/NCT03886012?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Conditions : Dizziness; Nausea; Headache; Confusion
Interventions : Device: Otoband; Device: Otoband sham
Sponsor : Otolith Labs
Not yet recruiting
Efficacy of a Transcranial Vibrating System for Mitigation of Migraine Associated Vertigo
NCT03886012
Fri, 22 Mar 2019 12:00:00 EDT
Last Update Posted: 03/22/19 09:27AM
https://clinicaltrials.gov/ct2/show/NCT03887325?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Headache, Migraine
Interventions : Drug: Maxipost; Drug: Saline
Sponsor : Danish Headache Center
Recruiting
The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients
NCT03887325
Fri, 22 Mar 2019 12:00:00 EDT
Last Update Posted: 03/22/19 09:26AM
https://clinicaltrials.gov/ct2/show/NCT03885154?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Condition : Migraine in Children
Interventions : Drug: Valproic Acid (VPA); Drug: Dihydroergotamine (DHE)
Sponsor : Kimberly S Jones
Recruiting
Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine
NCT03885154
Thu, 21 Mar 2019 12:00:00 EDT
Last Update Posted: 03/21/19 09:51AM
https://clinicaltrials.gov/ct2/show/NCT03877718?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14
Conditions : Migraine; Pain; Nausea; Vomiting; Aura
Interventions : Drug: Arm 1: CL-H1T; Drug: Arm 2: CL-H1T; Drug: Arm 3: Sumatriptan Succinate 100 mg capsule; Drug: Arm 4: Promethazine HCl 18.75 mg; Drug: Arm 5: Promethazine HCl 37.5 mg; Other: Placebo
Sponsor : Charleston Laboratories, Inc
Recruiting
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
NCT03877718
Mon, 18 Mar 2019 12:00:00 EDT
Last Update Posted: 03/18/19 10:46AM
https://clinicaltrials.gov/ct2/show/NCT03488563?type=Intr&cond=Migraine&lupd_s=03%2F01%2F2019&lupd_d=14
Condition : Migraine
Interventions : Biological: B244; Biological: Vehicle
Sponsors : AOBiome LLC; Veristat, Inc.
Active, not recruiting
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
NCT03488563
Thu, 05 Apr 2018 12:00:00 EDT
Last Update Posted: 03/15/19 11:30AM
https://clinicaltrials.gov/ct2/show/NCT03401346?type=Intr&cond=Migraine&lupd_s=03%2F01%2F2019&lupd_d=14
Condition : Migraine Headache
Interventions : Combination Product: INP104; Drug: Dihydroergotamine Mesylate (DHE); Combination Product: Migranal Nasal Spray
Sponsor : Impel NeuroPharma Inc.
Completed
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
NCT03401346
Wed, 17 Jan 2018 12:00:00 EST
Last Update Posted: 03/15/19 11:30AM
https://clinicaltrials.gov/ct2/show/NCT03874832?type=Intr&cond=Migraine&lupd_s=02%2F28%2F2019&lupd_d=14
Conditions : Migraine With Aura; Migraine Without Aura; Migraine
Intervention : Drug: Dihydroergotamine
Sponsor : Satsuma Pharmaceuticals, Inc.
Completed
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
NCT03874832
Thu, 14 Mar 2019 12:00:00 EDT
Last Update Posted: 03/14/19 09:43AM
https://clinicaltrials.gov/ct2/show/NCT03874351?type=Intr&cond=Migraine&lupd_s=02%2F28%2F2019&lupd_d=14
Condition : Migraine Disorders
Intervention : Device: non-invasive transcranial direct current stimulation (tDCS)
Sponsors : MJHS Institute for Innovation in Palliative Care; New York Headache Center
Not yet recruiting
A Study of Home-Delivered Neurostimulation for Migraine
NCT03874351
Thu, 14 Mar 2019 12:00:00 EDT
Last Update Posted: 03/14/19 09:43AM
https://clinicaltrials.gov/ct2/show/NCT03303105?type=Intr&cond=Migraine&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Migraine
Intervention : Drug: TEV-48125
Sponsor : Otsuka Pharmaceutical Co., Ltd.
Recruiting
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
NCT03303105
Thu, 05 Oct 2017 12:00:00 EDT
Last Update Posted: 03/13/19 10:21AM
https://clinicaltrials.gov/ct2/show/NCT02630459?type=Intr&cond=Migraine&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Migraine
Interventions : Drug: Placebo; Drug: Erenumab
Sponsor : Amgen
Active, not recruiting
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
NCT02630459
Tue, 15 Dec 2015 12:00:00 EST
Last Update Posted: 03/13/19 10:21AM
https://clinicaltrials.gov/ct2/show/NCT03872453?type=Intr&cond=Migraine&lupd_s=02%2F27%2F2019&lupd_d=14
Condition : Migraine
Interventions : Drug: BHV3500 10mg; Drug: BHV3500 20mg; Drug: BHV3500 5mg; Drug: BHV3500 matching placebo; Device: Intranasal Aptar Pharma Unit Dose System
Sponsor : Biohaven Pharmaceuticals, Inc.
Not yet recruiting
Acute Treatment Trial in Adult Subjects With Migraines
NCT03872453
Wed, 13 Mar 2019 12:00:00 EDT
Last Update Posted: 03/13/19 10:21AM
https://clinicaltrials.gov/ct2/show/NCT03867864?type=Intr&cond=Migraine&lupd_s=02%2F22%2F2019&lupd_d=14
Conditions : Headache, Migraine; Quality of Life
Interventions : Device: Necklace with essential oil for the first 4 weeks; Device: Necklace without essential oil for the first 4 weeks; Other: Washout; Device: Necklace with essential oil for last 4 weeks; Device: Necklace without essential oil for last 4 weeks
Sponsor : National Taiwan University Hospital
Not yet recruiting
Effects of Aromatherapy on the Headache and Service Quality Among Nurses Working in Critical Care Nurses Units.
NCT03867864
Fri, 08 Mar 2019 12:00:00 EST
Last Update Posted: 03/08/19 12:00PM
https://clinicaltrials.gov/ct2/show/NCT03700320?type=Intr&cond=Migraine&lupd_s=02%2F22%2F2019&lupd_d=14
Condition : Episodic Migraine
Interventions : Drug: Atogepant 60 mg; Drug: Standard of Care (SOC) Migraine Prevention Medication
Sponsor : Allergan
Recruiting
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
NCT03700320
Tue, 09 Oct 2018 12:00:00 EDT
Last Update Posted: 03/08/19 12:00PM
https://clinicaltrials.gov/ct2/show/NCT03338920?type=Intr&cond=Migraine&lupd_s=02%2F21%2F2019&lupd_d=14
Condition : Acute Migraine With or Without Aura
Interventions : Drug: sumatriptan nasal powder; Drug: Placebo
Sponsor : Avanir Pharmaceuticals
Recruiting
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
NCT03338920
Thu, 09 Nov 2017 12:00:00 EST
Last Update Posted: 03/07/19 09:36AM
https://clinicaltrials.gov/ct2/show/NCT03867201?type=Intr&cond=Migraine&lupd_s=02%2F21%2F2019&lupd_d=14
https://clinicaltrials.gov/ct2/show/NCT03867201?type=Intr&cond=Migraine&lupd_s=02%2F21%2F2019&lupd_d=14
Condition : Migraine
Interventions : Biological: Erenumab; Other: Placebo
Sponsor : Novartis Pharmaceuticals
Not yet recruiting
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
NCT03867201
Thu, 07 Mar 2019 12:00:00 EST
Last Update Posted: 03/07/19 09:36AM
https://clinicaltrials.gov/ct2/show/NCT03694626?type=Intr&cond=Migraine&lupd_s=02%2F20%2F2019&lupd_d=14
Conditions : Photophobia; Traumatic Brain Injury; Migraine
Interventions : Device: Pupillography; Device: Ocular Coherence Tomography (OCT); Device: Wrist-watch sensor device; Device: Videography; Device: Electrophysiology
Sponsor : Randy Kardon
Not yet recruiting
Objectively Diagnose and Monitor Treatment of Light Sensitivity
NCT03694626
Wed, 03 Oct 2018 12:00:00 EDT
Last Update Posted: 03/06/19 09:19AM
https://clinicaltrials.gov/ct2/show/NCT03333109
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (EMPOwER)
https://clinicaltrials.gov/ct2/show/NCT03266588
Open Label Safety Study in Acute Treatment of Migraine
A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine
